Business
Presents at the Diabetes Asia 2017 Conference
Presents at the Diabetes Asia 2017 Conference.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 4967T Oxford BioDynamics PLC 13 October 2017 \n\n \n13 October 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics presents at the Diabetes Asia 2017 Conference \n \nEpiSwitch™ successful in stratifying patients into different stages of type 2 diabetes \n \nOxford BioDynamics Plc (\"OBD\" or the \"Company\"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that it has presented a poster at The Diabetes Asia 2017 Conference, 12-15 October 2017 in Kuala Lumpur, Malaysia.\n \nThe poster entitled: \"Glycaemic Progression Study Among Population in Penang, Malaysia\" was presented from 2.00pm-3.30pm local time on 12 October 2017.\n \nType 2 diabetes mellitus (T2D) is a fast growing health threat with increasing prevalence in Asian populations. From 2006 to 2011, the prevalence of T2D in Malaysia increased by 31%1. Interestingly, most patients with T2D pass through a 'pre-diabetes' phase, where the biochemical threshold for diagnosis has not been reached. Clinical trials have shown that the risk of progression to T2D can be reduced in the pre-diabetes phase. \n \nIn this study, 270 people were separated into groups dependent on their diabetes status (healthy, pre-diabetes, diabetes treatment-naive and diabetes with treatment). The glycaemic progression of these individuals was followed-up at six months. After six months, it was found that 44% of participants in the pre-diabetes stage regressed to the healthy stage, however only 4% of participants with diabetes regressed to the healthy stage. Using epigenetic biomarkers identified by OBD's EpiSwitch™ technology, individuals could be accurately stratified to identify those in the pre-diabetes phase, the phase at which diabetes is most likely to be prevented. \n \nDr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: \n \n\"This study demonstrates that there is considerable clinical utility in using our EpiSwitch™ technology to identify those at the pre-diabetic phase, and could be a powerful tool in tackling...